Discontinued — last reported Q1 '18
Linde Allowance for Doubtful Accounts Receivable (Current) decreased by 1.5% to $453.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric declined by 4.0%, from $472.00M to $453.00M. Over 4 years (FY 2020 to FY 2024), Allowance for Doubtful Accounts Receivable (Current) shows a downward trend with a -2.8% CAGR. This is a positive signal — lower values indicate better performance for this metric.
A significant increase relative to receivables may signal deteriorating customer credit quality or economic headwinds in specific markets.
This is a contra-asset account representing the estimated amount of accounts receivable that the company expects will no...
Standard across all industries; peers in the medical device sector typically maintain low levels unless operating in high-risk emerging markets.
allowance_for_doubtful_accounts_receivable_current| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $430.00M | $423.00M | $405.00M | $399.00M | $396.00M | $377.00M | $405.00M | $426.00M | $426.00M | $446.00M | $457.00M | $450.00M | $458.00M | $472.00M | $421.00M | $420.00M | $460.00M | $453.00M |
| QoQ Change | — | -1.6% | -4.3% | -1.5% | -0.8% | -4.8% | +7.4% | +5.2% | +0.0% | +4.7% | +2.5% | -1.5% | +1.8% | +3.1% | -10.8% | -0.2% | +9.5% | -1.5% |
| YoY Change | — | — | — | — | -7.9% | -10.9% | +0.0% | +6.8% | +7.6% | +18.3% | +12.8% | +5.6% | +7.5% | +5.8% | -7.9% | -6.7% | +0.4% | -4.0% |
We use cookies for analytics. See our Privacy and Cookie Policy.